

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

SciClone Announces First Subject Dosed in Phase III Clinical Trial of Vaborem® in China

This announcement is made by SciClone Pharmaceuticals (Holdings) Limited (the “**Company**” or “**SciClone**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders of the Company (the “**Shareholders**”) and potential investors informed on the latest business development of the Group.

The Company is pleased to announce that the first subject has been dosed in the Phase III clinical trial of Vaborem® (Meropenem and Vaborbactam for injection) (“**Vaborem**®”) in China, a new antibacterial drug.

This study is a Phase III, randomized, double-blind, double-dummy, active-controlled, multi-center clinical trial to be conducted in China to evaluate the efficacy and safety of Vaborem® for patients with complicated urinary tract infections (“**cUTI**”) including pyelonephritis. The results of this study and a concurrent study in healthy volunteers in China to evaluate the pharmacokinetic profile of Vaborem®, are meant to bridge the foreign clinical trial data and eventually support the New Drug Application (“**NDA**”) of Vaborem® in China.

Vaborem® is a fixed-dose combination of a carbapenem and a novel boronic acid β -lactamase inhibitor of class A and Class C serine β -lactamase. Vaborbactam can inhibit various class A and class C β -lactamases, so it protects meropenem from degradation by serine carbapenemases, restoring meropenem’s activity against carbapenem-resistant strains. Vaborem® has been specifically developed to inhibit carbapenem-resistant enterobacterales

(“CRE”) including the commonly found *Klebsiella pneumoniae* carbapenemase (“KPC”)-producing bacteria. Currently Vaborem® has been granted marketing authorizations in the United States of America and the European Union, among other countries and regions, for adults with cUTI including pyelonephritis. In select territories, it has also been approved for the treatment of complicated intra-abdominal infections (“cIAI”), hospital-acquired bacterial pneumonia (“HABP”) and ventilator-associated bacterial pneumonia (“VABP”).

Pursuant to the License and Collaboration Agreement entered into between SciClone Pharmaceuticals and A. Menarini Asia-Pacific Holdings Pte. Ltd., part of The Menarini Group (“Menarini”), in August 2022, the Company has the exclusive right to develop and commercialize Vaborem® in China, under Menarini’s head license agreement with Melinta Therapeutics, Inc.. In March 2023, the National Medical Products Administration (the “NMPA”) in China officially approved the Company’s Investigational New Drug (the “IND”) application for Vaborem®.

There is a continuous demand in China for novel anti-infectives that can effectively treat multidrug-resistant infections, as unmet medical needs persist. The Company looks forward to bringing Vaborem®, a novel antibiotic, to China through our collaboration with Menarini. Thanks to the collaborative efforts of the investigators, our partners and the Company, the first subject has been dosed in Vaborem® Phase III clinical trial in China. The Company will accelerate the clinical development of Vaborem® and hope to provide more effective and safer treatment options as soon as possible for patients in China suffering from life threatening, multidrug-resistant infections.

The Group cannot guarantee that the above mentioned clinical studies of Vaborem® will ultimately be successfully completed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

About the Company:

SciClone is a global biopharmaceutical company with an integrated platform for the development and commercialization of innovative therapies for cancer and severe infection. With an innovation-driven strategic transformation, SciClone has established a product portfolio with differentiated advantages, including a number of first-in-class and best-in-class potential products/pipelines. Staying true to the Group’s original aspiration of “SciClone gives life hope”, SciClone is dedicated to improving patients’ health by providing top-tier healthcare products and services with global standards of care. For more information about the Company, please visit www.sciclone.com.

DEFINITIONS

“China” the People’s Republic of China; for the purposes of this announcement only and except where the context requires otherwise, excludes Hong Kong, Macau and Taiwan

By order of the Board
SciClone Pharmaceuticals (Holdings) Limited
ZHAO Hong
Executive Director, Chief Executive Officer and President

Hong Kong, July 5, 2023

As at the date of this announcement, the Board comprises Mr. Zhao Hong and Ms. Pan Rongrong as executive directors, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* *for identification purpose only*